MX2021009384A - Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. - Google Patents
Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico.Info
- Publication number
- MX2021009384A MX2021009384A MX2021009384A MX2021009384A MX2021009384A MX 2021009384 A MX2021009384 A MX 2021009384A MX 2021009384 A MX2021009384 A MX 2021009384A MX 2021009384 A MX2021009384 A MX 2021009384A MX 2021009384 A MX2021009384 A MX 2021009384A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- lysosomal storage
- storage diseases
- disorders associated
- treating symptoms
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 208000035475 disorder Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000015439 Lysosomal storage disease Diseases 0.000 title abstract 2
- 208000024891 symptom Diseases 0.000 title abstract 2
- 208000004998 Abdominal Pain Diseases 0.000 abstract 1
- 208000024720 Fabry Disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 201000009431 angiokeratoma Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 238000002641 enzyme replacement therapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- -1 quinuclidine compound Chemical class 0.000 abstract 1
- 150000008584 quinuclidines Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente descripción se refiere a métodos para tratar o prevenir particulares síntomas y trastornos que se asocian con enfermedades del almacenamiento lisosómico utilizando compuestos de quinuclidina de la fórmula (I), opcionalmente combinados con terapia de reemplazo enzimático. Esto incluye dolor, tal como dolor abdominal, y trastornos dermatológicos, tal como angioqueratoma, en un paciente que tiene una enfermedad, tal como la enfermedad de Fabry. También se describe una composición farmacéutica que comprende un compuesto de quinuclidina para usarse en dichos métodos.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800996P | 2019-02-04 | 2019-02-04 | |
| US201962851433P | 2019-05-22 | 2019-05-22 | |
| US201962894167P | 2019-08-30 | 2019-08-30 | |
| US201962937618P | 2019-11-19 | 2019-11-19 | |
| US202062962647P | 2020-01-17 | 2020-01-17 | |
| PCT/US2020/016440 WO2020163244A1 (en) | 2019-02-04 | 2020-02-03 | Methods for treating symptoms and disorders associated with lysosomal storage diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009384A true MX2021009384A (es) | 2021-09-10 |
Family
ID=69743942
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009384A MX2021009384A (es) | 2019-02-04 | 2020-02-03 | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. |
| MX2021009383A MX2021009383A (es) | 2019-02-04 | 2020-02-03 | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009383A MX2021009383A (es) | 2019-02-04 | 2020-02-03 | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220016092A1 (es) |
| EP (2) | EP3920913A1 (es) |
| JP (2) | JP2022520747A (es) |
| KR (2) | KR20210123353A (es) |
| CN (2) | CN113645969A (es) |
| AU (2) | AU2020218496A1 (es) |
| BR (2) | BR112021015099A2 (es) |
| CA (2) | CA3128039A1 (es) |
| IL (3) | IL313808A (es) |
| MX (2) | MX2021009384A (es) |
| SG (2) | SG11202107842QA (es) |
| TW (2) | TW202045168A (es) |
| WO (2) | WO2020163245A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20130273B1 (ar) | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| IL295255A (en) | 2020-02-03 | 2022-10-01 | Genzyme Corp | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| CA3186766A1 (en) | 2020-07-24 | 2022-01-27 | Danielle Combessis | Pharmaceutical compositions comprising venglustat |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (es) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| RU2645675C2 (ru) | 2011-03-18 | 2018-02-27 | Джензим Корпорейшн | Ингибиторы глюкозилцерамид-синтазы |
| WO2015089067A1 (en) | 2013-12-11 | 2015-06-18 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
-
2020
- 2020-02-03 KR KR1020217027946A patent/KR20210123353A/ko active Search and Examination
- 2020-02-03 JP JP2021545375A patent/JP2022520747A/ja active Pending
- 2020-02-03 SG SG11202107842QA patent/SG11202107842QA/en unknown
- 2020-02-03 EP EP20709405.3A patent/EP3920913A1/en active Pending
- 2020-02-03 CA CA3128039A patent/CA3128039A1/en active Pending
- 2020-02-03 WO PCT/US2020/016441 patent/WO2020163245A1/en unknown
- 2020-02-03 CN CN202080025346.0A patent/CN113645969A/zh active Pending
- 2020-02-03 CN CN202080025266.5A patent/CN113710249A/zh active Pending
- 2020-02-03 MX MX2021009384A patent/MX2021009384A/es unknown
- 2020-02-03 IL IL313808A patent/IL313808A/en unknown
- 2020-02-03 US US17/428,505 patent/US20220016092A1/en active Pending
- 2020-02-03 EP EP20709406.1A patent/EP3920914A1/en active Pending
- 2020-02-03 AU AU2020218496A patent/AU2020218496A1/en active Pending
- 2020-02-03 SG SG11202107844UA patent/SG11202107844UA/en unknown
- 2020-02-03 MX MX2021009383A patent/MX2021009383A/es unknown
- 2020-02-03 AU AU2020217659A patent/AU2020217659A1/en active Pending
- 2020-02-03 US US17/428,504 patent/US20220023273A1/en active Pending
- 2020-02-03 JP JP2021545383A patent/JP7511567B2/ja active Active
- 2020-02-03 BR BR112021015099-4A patent/BR112021015099A2/pt unknown
- 2020-02-03 WO PCT/US2020/016440 patent/WO2020163244A1/en unknown
- 2020-02-03 BR BR112021015172-9A patent/BR112021015172A2/pt unknown
- 2020-02-03 CA CA3128041A patent/CA3128041A1/en active Pending
- 2020-02-03 KR KR1020217027945A patent/KR20210123352A/ko active Search and Examination
- 2020-02-04 TW TW109103398A patent/TW202045168A/zh unknown
- 2020-02-04 TW TW109103397A patent/TW202045167A/zh unknown
-
2021
- 2021-07-28 IL IL285187A patent/IL285187A/en unknown
- 2021-08-02 IL IL285304A patent/IL285304A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113645969A (zh) | 2021-11-12 |
| AU2020218496A1 (en) | 2021-08-26 |
| SG11202107842QA (en) | 2021-08-30 |
| BR112021015172A2 (pt) | 2021-09-28 |
| TW202045167A (zh) | 2020-12-16 |
| JP7511567B2 (ja) | 2024-07-05 |
| KR20210123352A (ko) | 2021-10-13 |
| TW202045168A (zh) | 2020-12-16 |
| US20220016092A1 (en) | 2022-01-20 |
| AU2020217659A1 (en) | 2021-08-26 |
| BR112021015099A2 (pt) | 2021-10-05 |
| KR20210123353A (ko) | 2021-10-13 |
| EP3920913A1 (en) | 2021-12-15 |
| US20220023273A1 (en) | 2022-01-27 |
| CA3128039A1 (en) | 2020-08-13 |
| WO2020163245A1 (en) | 2020-08-13 |
| IL285304A (en) | 2021-09-30 |
| EP3920914A1 (en) | 2021-12-15 |
| WO2020163244A1 (en) | 2020-08-13 |
| SG11202107844UA (en) | 2021-08-30 |
| IL285187A (en) | 2021-09-30 |
| MX2021009383A (es) | 2021-09-10 |
| JP2022519274A (ja) | 2022-03-22 |
| CN113710249A (zh) | 2021-11-26 |
| JP2022520747A (ja) | 2022-04-01 |
| CA3128041A1 (en) | 2020-08-13 |
| IL313808A (en) | 2024-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009384A (es) | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. | |
| MX2021007970A (es) | Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo. | |
| ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
| MX2014002459A (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. | |
| MX2011007854A (es) | Metodos para tratar infartos agudos al miocardio y trastornos relacionados. | |
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| EP1933833B8 (en) | Therapy for the treatment of overactive bladder | |
| MX2014002460A (es) | Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmaceuticas y metodos para uso. | |
| MX2014001088A (es) | Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas. | |
| MX2009008228A (es) | N-adamantil benzamidas como inhibidores de la dehidrogenasa 11-beta-hidroxiesteroide. | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| MX2021007592A (es) | Compuestos macrociclicos y su uso en el tratamiento de enfermedades. | |
| MX2023005455A (es) | Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil. | |
| MX2021015498A (es) | Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades. | |
| MX2009004561A (es) | Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor. | |
| BR112013005673A2 (pt) | uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes | |
| RS20080497A (en) | Novel low dose pharmaceutical compositions comrising nimesulide, preparation and use thereof | |
| MX2011009709A (es) | Compuestos para el tratamiento de la inflamacion y del dolor. | |
| CR20220036A (es) | Derivados de 2h-indazol y su uso en el tratamiento de enfermedades | |
| MX2011010732A (es) | Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer. | |
| MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
| MX2022009874A (es) | Inhibidores heterociclicos de peptidil arginina desiminasa 4 (pad4). | |
| EP4389218A3 (en) | Composition for treating joint disease and kit containing same | |
| MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. |